Brief: Glenmark Pharmaceuticals Says No Dose-Limiting Toxicities Observed In ISB 2001 Study
10/12/2024 04:43
Dec 10 (Reuters) - Glenmark Pharmaceuticals Ltd
GLEN.NS :
* IGI PRESENTS PHASE 1 DATA FOR ISB 2001 SHOWING HIGH ORR
* NO DOSE-LIMITING TOXICITIES OBSERVED IN ISB 2001 STUDY
Source text: ID:nNSEM8KQ0
Further company coverage: GLEN.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter